Target Name: MIR933
NCBI ID: G100126350
Review Report on MIR933 Target / Biomarker Content of Review Report on MIR933 Target / Biomarker
Other Name(s): mir-933 | hsa-miR-933 | hsa-mir-933 | microRNA 933 | MicroRNA 933 | MIRN933

Introduction to MIR933
MIR933: An Emerging Biomarker and Potential Drug Target

In recent years, the discovery of microRNAs (miRNAs) has revolutionized our understanding of gene regulation and their potential involvement in various disease pathways. miRNAs are small, non-coding RNA molecules that play a crucial role in post-transcriptional gene silencing. One such promising miRNA that has garnered increasing attention is MIR933. This article aims to shed light on the significance of MIR933 as both a biomarker and a potential drug target.

The Role of MIR933 in Disease:
Over the past decade, extensive research has established a link between dysregulation of miRNAs and various diseases, including cancer, cardiovascular disorders, neurological conditions, and immune dysfunction. miRNAs such as MIR933 have been shown to act as either tumor suppressors or oncogenes, depending on the specific cellular context.

In terms of cancer, MIR933 has been associated with different types, including breast, lung, liver, and colorectal cancer. Studies have demonstrated that MIR933 expression is significantly altered in tumor tissues compared to adjacent normal tissues, suggesting its potential involvement in cancer initiation and progression. Furthermore, several investigations have implicated MIR933 in metastasis, chemotherapy resistance, and prognosis, highlighting its importance as a diagnostic and prognostic biomarker.

In addition to cancer, increased levels of MIR933 have been reported in cardiovascular disorders such as atherosclerosis and myocardial infarction. Its deregulation has been linked to the dysfunction of endothelial cells, smooth muscle cells, and cardiomyocytes, thereby contributing to the development of cardiovascular pathologies. Furthermore, MIR933 has also been found to modulate immune responses and affect the pathogenesis of autoimmune disorders, making it an intriguing target for therapeutic intervention.

MIR933 as a Diagnostic Biomarker:
The discovery of specific miRNA signatures in various diseases has paved the way for their potential use as diagnostic biomarkers. MIR933, with its aberrant expression in multiple diseases, holds great promise as a non-invasive and reliable biomarker for early disease detection and monitoring.

Studies have shown that MIR933 can be readily detected in biofluids such as blood, urine, saliva, and even exosomes. The stability of miRNAs in these biofluids, coupled with the development of robust and sensitive techniques for miRNA detection, has opened the door for their potential use in routine clinical practice. The ability to measure MIR933 levels in easily accessible biofluids could revolutionize disease detection, allowing for earlier intervention and better patient outcomes.

MIR933 as a Therapeutic Target:
The dysregulation of miRNAs in disease pathogenesis has led to the emergence of miRNA-based therapeutics, which hold great promise for precision medicine. Harnessing the potential of MIR933 as a therapeutic target could revolutionize treatment strategies for various diseases.

Several approaches have been explored for modulating miRNA expression, including miRNA mimics, antisense oligonucleotides, and small molecule inhibitors. By selectively targeting MIR933, it may be possible to restore its normal expression levels or silence its expression, depending on the specific disease context. The development of targeted therapies against MIR933 could have far-reaching implications in precision medicine, allowing for more effective and personalized treatments tailored to the individual patient.

In conclusion, MIR933 is an emerging biomarker and potential drug target that holds great promise in the field of medical research and clinical practice. Its dysregulation in various diseases, coupled with its detectability in biofluids, makes it an attractive candidate for diagnostic purposes. Furthermore, the ability to therapeutically target MIR933 opens new avenues for precision medicine and personalized treatments. As research on MIR933 continues to unfold, its potential applications in disease diagnosis, monitoring, and treatment are likely to significantly impact healthcare practices in the near future.

Protein Name: MicroRNA 933

The "MIR933 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR933 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

MIR934 | MIR935 | MIR936 | MIR937 | MIR938 | MIR939 | MIR940 | MIR941-1 | MIR941-2 | MIR941-3 | MIR941-4 | MIR941-5 | MIR942 | MIR943 | MIR944 | MIR95 | MIR96 | MIR98 | MIR99A | MIR99AHG | MIR99B | MIRLET7 | MIRLET7A1 | MIRLET7A2 | MIRLET7A3 | MIRLET7B | MIRLET7BHG | MIRLET7C | MIRLET7D | MIRLET7E | MIRLET7F1 | MIRLET7F2 | MIRLET7G | MIRLET7I | MIS12 | MIS12 complex | MIS18A | MIS18A-AS1 | MIS18BP1 | MISFA | MISP | MISP3 | MITD1 | MITF | Mitochondrial complex I assembly complex | Mitochondrial import inner membrane translocase 23 (TIM23) complex | Mitochondrial inner membrane protease complex | Mitochondrial membrane ATP synthase | Mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) | Mitochondrial pyruvate carrier complex (MPC) | Mitochondrial RNA processing endoribonuclease | Mitofilin Complex | Mitofusin | Mitogen-Activated Protein Kinase | Mitogen-activated protein kinase (JNK) | Mitogen-Activated Protein Kinase (MAP Kinase)-Activated Protein Kinase | Mitogen-Activated Protein Kinase Kinase Kinase (MAP3K) | Mitogen-activated protein kinase p38 (MAPK p38) | MITRAC complex | MIX23 | MIXL1 | MKI67 | MKKS | MKLN1 | MKLN1-AS | MKNK1 | MKNK1-AS1 | MKNK2 | MKRN1 | MKRN2 | MKRN2OS | MKRN3 | MKRN4P | MKRN7P | MKRN9P | MKS1 | MKX | MLANA | MLC1 | MLEC | MLF1 | MLF1-DT | MLF2 | MLH1 | MLH3 | MLIP | MLIP-AS1 | MLKL | MLLT1 | MLLT10 | MLLT10P1 | MLLT11 | MLLT3 | MLLT6 | MLN | MLNR | MLPH | MLST8 | MLX | MLXIP